MX2025007881A - Anticuerpos que se unen a histona 2a y/o 4 citrulinada - Google Patents
Anticuerpos que se unen a histona 2a y/o 4 citrulinadaInfo
- Publication number
- MX2025007881A MX2025007881A MX2025007881A MX2025007881A MX2025007881A MX 2025007881 A MX2025007881 A MX 2025007881A MX 2025007881 A MX2025007881 A MX 2025007881A MX 2025007881 A MX2025007881 A MX 2025007881A MX 2025007881 A MX2025007881 A MX 2025007881A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies binding
- citrullinated histone
- antibodies
- binding fragments
- citrullinated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
| GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
| PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025007881A true MX2025007881A (es) | 2025-08-01 |
Family
ID=67688785
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025007881A MX2025007881A (es) | 2018-08-21 | 2019-08-20 | Anticuerpos que se unen a histona 2a y/o 4 citrulinada |
| MX2021001902A MX2021001902A (es) | 2018-08-21 | 2019-08-20 | Anticuerpos que se unen a histona 2a y/o 4 citrulinada. |
| MX2025007882A MX2025007882A (es) | 2018-08-21 | 2021-02-17 | Anticuerpos que se unen a histona 2a y/o 4 citrulinada |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001902A MX2021001902A (es) | 2018-08-21 | 2019-08-20 | Anticuerpos que se unen a histona 2a y/o 4 citrulinada. |
| MX2025007882A MX2025007882A (es) | 2018-08-21 | 2021-02-17 | Anticuerpos que se unen a histona 2a y/o 4 citrulinada |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20210395350A1 (https=) |
| EP (2) | EP3841120B1 (https=) |
| JP (2) | JP7434328B2 (https=) |
| KR (2) | KR20250148711A (https=) |
| CN (2) | CN120058926A (https=) |
| AU (3) | AU2019326740B2 (https=) |
| CA (1) | CA3110013A1 (https=) |
| DK (1) | DK3841120T3 (https=) |
| ES (1) | ES3048210T3 (https=) |
| FI (1) | FI3841120T3 (https=) |
| HR (1) | HRP20251346T1 (https=) |
| IL (2) | IL280995B2 (https=) |
| LT (1) | LT3841120T (https=) |
| MX (3) | MX2025007881A (https=) |
| PT (1) | PT3841120T (https=) |
| RS (1) | RS67385B1 (https=) |
| SG (1) | SG11202101652PA (https=) |
| SI (1) | SI3841120T1 (https=) |
| SM (1) | SMT202500388T1 (https=) |
| WO (1) | WO2020038963A1 (https=) |
| ZA (1) | ZA202101051B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| EP3841120B1 (en) | 2018-08-21 | 2025-09-24 | Citryll B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
| AU2019354829B2 (en) | 2018-10-05 | 2025-04-17 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms |
| WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
| CA3183196A1 (en) * | 2020-07-07 | 2022-01-13 | Steven D. Goodman | Combination therapies for the treatment and prevention of biofilms |
| GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| KR20240005856A (ko) | 2021-05-04 | 2024-01-12 | 씨트릴 비.브이. | 세포 외 트랩 억제 |
| EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) * | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| NO2294086T3 (https=) | 2008-06-04 | 2018-02-10 | ||
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
| JP7037940B2 (ja) * | 2014-12-11 | 2022-03-17 | シトリル べー．フェー． | 特発性肺線維症の治療方法 |
| US20170038381A1 (en) | 2015-08-06 | 2017-02-09 | Novimmune Sa | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| EP3841120B1 (en) | 2018-08-21 | 2025-09-24 | Citryll B.V. | Antibodies binding to citrullinated histone 2a and/or 4 |
| CN117396221A (zh) * | 2021-05-04 | 2024-01-12 | 奇特里尔私人有限公司 | 嗜酸性粒细胞陷阱的抑制 |
| KR20240005856A (ko) | 2021-05-04 | 2024-01-12 | 씨트릴 비.브이. | 세포 외 트랩 억제 |
-
2019
- 2019-08-20 EP EP19756180.6A patent/EP3841120B1/en active Active
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/ja active Active
- 2019-08-20 SM SM20250388T patent/SMT202500388T1/it unknown
- 2019-08-20 RS RS20251114A patent/RS67385B1/sr unknown
- 2019-08-20 CN CN202510240710.XA patent/CN120058926A/zh active Pending
- 2019-08-20 MX MX2025007881A patent/MX2025007881A/es unknown
- 2019-08-20 KR KR1020257029356A patent/KR20250148711A/ko active Pending
- 2019-08-20 CN CN201980070130.3A patent/CN112930356B/zh active Active
- 2019-08-20 FI FIEP19756180.6T patent/FI3841120T3/fi active
- 2019-08-20 DK DK19756180.6T patent/DK3841120T3/da active
- 2019-08-20 EP EP25196231.2A patent/EP4659807A3/en active Pending
- 2019-08-20 HR HRP20251346TT patent/HRP20251346T1/hr unknown
- 2019-08-20 IL IL280995A patent/IL280995B2/en unknown
- 2019-08-20 PT PT197561806T patent/PT3841120T/pt unknown
- 2019-08-20 IL IL322482A patent/IL322482A/en unknown
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/es unknown
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 LT LTEPPCT/EP2019/072302T patent/LT3841120T/lt unknown
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en not_active Ceased
- 2019-08-20 SI SI201930975T patent/SI3841120T1/sl unknown
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 AU AU2019326740A patent/AU2019326740B2/en active Active
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 ES ES19756180T patent/ES3048210T3/es active Active
- 2019-08-20 KR KR1020217008362A patent/KR102871821B1/ko active Active
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-17 MX MX2025007882A patent/MX2025007882A/es unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US12590143B2/en active Active
-
2024
- 2024-02-06 JP JP2024016700A patent/JP7835788B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201303A patent/AU2026201303A1/en active Pending
- 2026-02-20 AU AU2026201302A patent/AU2026201302A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025007882A (es) | Anticuerpos que se unen a histona 2a y/o 4 citrulinada | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| ZA202100723B (en) | Fc binding fragments comprising a cd137 antigen-binding site | |
| NZ782442A (en) | Antibodies that bind cd39 and uses thereof | |
| MY202336A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| PH12016502064A1 (en) | Human antibodies to middle east respiratory syndrome-coronavirus spike protein | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| MX2023004333A (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. | |
| MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| WO2018069871A3 (en) | Anti-kras binding proteins | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. | |
| EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |